Stocks and Investing Stocks and Investing
Wed, June 29, 2022
Tue, June 28, 2022
Mon, June 27, 2022
Fri, June 24, 2022

Kristen Kluska Maintained (SRPT) at Buy with Decreased Target to $128 on, Jun 24th, 2022


Published on 2024-10-27 21:37:01 - WOPRAI, Kristen Kluska
  Print publication without navigation


Kristen Kluska of Cantor Fitzgerald, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Buy with Decreased Target from $140 to $128 on, Jun 24th, 2022.

Kristen has made no other calls on SRPT in the last 4 months.



There are 3 other peers that have a rating on SRPT. Out of the 3 peers that are also analyzing SRPT, 1 agrees with Kristen's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Matthew Harrison of "Morgan Stanley" Maintained at Hold with Decreased Target to $74 on, Thursday, May 19th, 2022


These are the ratings of the 2 analyists that currently disagree with Kristen


  • Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy with Increased Target to $107 on, Tuesday, April 19th, 2022
  • Brian Abrahams of "RBC Capital" Maintained at Buy with Increased Target to $150 on, Wednesday, March 2nd, 2022